Validation Study on the Utility of Immunoglobulin Heavy/Light Chain Immunofluorescence in Kidney Biopsies With Potential Monoclonal Gammopathy of Renal Significance Lesions

Satoru Kudose1, Geetha Jagannathan1, Dominick Santoriello1, Miroslav Sekulic1, Ibrahim Batal1, M. Barry Stokes1, Vivette D. D’Agati1 and Glen S. Markowitz1

1Department of Pathology and Cell Biology, Columbia University Irving Medical Center, New York, New York, USA

Correspondence: Satoru Kudose, Department of Pathology and Cell Biology, Columbia University Irving Medical Center, Room VC14-238, 630 West 168th Street, New York, New York 10032, USA. E-mail: sk4521@cumc.columbia.edu

Received 6 January 2022; revised 31 January 2022; accepted 31 January 2022; published online 5 February 2022

Kidney Int Rep (2022) 7, 1119–1122; https://doi.org/10.1016/j.ekir.2022.01.1071

KEYWORDS: heavy/light chain immunofluorescence; kidney biopsy; monoclonal gammopathy of renal significance

© 2022 International Society of Nephrology. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

Conventional immunofluorescence (IF) for kidney biopsies is generally performed on frozen sections and uses a panel of polyclonal antibodies directed against the constant regions of immunoglobulin heavy chains and light chains (LCs). Diagnosis of monoclonal gammopathy of renal significance (MGRS) currently relies on the detection of isotype and LC-restricted (monotypic) staining for heavy and LCs, supplemented by IgG subclass staining and paraffin IF in selected cases. Recently, Nasr et al.1 described the potential use of IF using polyclonal antibodies directed against the conformational epitope at the junction of the heavy and LC (HLC) constant regions (HLC-IF), including IgGk, IgGl, IgMk, IgMl, IgAk, and IgAl, for the evaluation of MGRS or other conditions with monotypic deposits.

Using these new antibodies, Nasr et al.1 found that some cases with apparent monotypic glomerular deposits by conventional IF (i.e., cases that stain for only 1 heavy chain isotype and only 1 LC) may have polytypic staining by HLC-IF with reactivity for both κ- and λ-heavy chain pairs. Therefore, HLC-IF could be used to confirm or exclude monotypic composition of deposits in these cases, similar to IgG subclass staining.1 Furthermore, they recommended that some cases that would be classified as MGRS based on conventional IF, such as proliferative glomerulonephritis (GN) with monoclonal immunoglobulin deposits (PGNMIDs), should not be categorized as MGRS if HLC-IF reveals staining for both IgGk and IgGl.1

Given the potentially utility of HLC-IF in the diagnosis of MGRS (Figure 1), we sought to broaden the clinical experience with HLC-IF in an independent series of kidney biopsies, enriched with entities that had relatively small sample size in the study by Nasr et al.1 Specifically, we evaluated 43 cases by direct HLC-IF for IgGk and IgGl and 22 cases by direct HLC-IF for IgAk and IgAl (including 12 controls; see Supplementary Methods).

Results are summarized in Table 1. There were 20 biopsies with PGNMID which exhibited, by definition, monotypic deposits by conventional IF, including 12 with IgG3k, 5 IgG1k, 1 IgG1l, 1 IgG2k, and 1 IgG3l. The cohort was unintentionally enriched with patients with malignancy or paraproteinemia including 1 patient with multiple myeloma and PGNMID-IgG3k, 3 patients with B-cell lymphoma (not further classified) including 2 with PGNMID-IgG3k and 1 with PGNMID-IgG2k, and 5 additional patients with a documented paraprotein (all PGNMID-IgG3k). HLC-IF results revealed both IgGk and IgGl in only 2 of 20 patients with PGNMID (10%), both of whom had IgG1k deposits by conventional IF. Of the 2 patients, 1 was 23 years old without detectable paraprotein or hematolymphoid malignancy and the other was 69 years old with free κ LCs on urine immunofixation but no hematolymphoid neoplasm.

HLC-IF was performed on 7 biopsies with immunitactoid GN (ITG) with monotypic deposits based on conventional IF with IgG subclass staining, including 3 with IgG1l, 2 IgG1k, and 2 IgG2k, and 1 with bitypic staining...
Among the 7 with monotypic ITG by conventional IF, 4 had chronic lymphocytic leukemia (including 2 patients with IgG1κ, 1 with IgG1λ, and 1 with IgG2κ deposits) and 2 had monoclonal gammopathy in the absence of chronic lymphocytic leukemia (1 with IgG1λ deposits and 1 with IgG2κ deposits). The remaining patient with monotypic ITG, and the patient with bityplic ITG, had no detectable paraprotein or hematolymphoid component.

Table 1. HLC-IF on independent samples of glomerular diseases with monotypic or bitypic deposits; comparison of results at Columbia University and Mayo Clinic

| Pathology                      | CUIMC                        | Mayo                        |
|--------------------------------|------------------------------|------------------------------|
|                                | Monotypic deposits by conventional IF | Number of cases polytypic by HLC-IF | Monotypic deposits by conventional IF | Number of cases polytypic by HLC-IF |
| PGNMID                         | IgG1κ                        | 2/5                          | IgG3κ                        | 2/7                          |
|                                | IgG1λ                        | 0/1                          | IgG3λ                        | 0/3                          |
|                                | IgG2κ                        | 0/1                          |                              |                              |
|                                | IgG3κ                        | 0/12                         |                              |                              |
|                                | IgG3λ                        | 0/1                          |                              |                              |
|                                | Total                        | 2/20                         | Total                        | 2/10                         |
| Immunotactoid GN               | IgG1κ                        | 2/2                          |                              |                              |
|                                | IgG1λ                        | 0/3                          |                              |                              |
|                                | IgG1κ and IgG2κ              | 1/1                          |                              |                              |
|                                | IgG2κ                        | 2/2                          |                              |                              |
|                                | Total                        | 5/8                          | Not evaluated                |                              |
| Monotypic or bitypic MN        | IgG1κ                        | 1/3                          |                              |                              |
|                                | IgG3λ                        | 0/1                          |                              |                              |
|                                | IgG1κ and IgG3κ              | 2/2                          | IgG3κ                        | 0/1                          |
|                                | Total                        | 3/6                          | Total                        | 0/1                          |
| Monotypic fibrillary GN        | IgG1κ                        | 2/3                          | IgG1κ                        | 3/6                          |
|                                | Total                        | 2/3                          | Total                        | 3/6                          |
| Monotypic or bitypic anti-GBM disease | IgG1κ                        | 2/2                          | IgG2κ                        | 0/1                          |
|                                | IgG1λ                        | 0/3                          | IgG1κ                        | 0/2                          |
|                                | IgG1κ and IgG4κ              | 1/1                          | IgMκ                         | 0/1                          |
|                                |                              |                               | IgAλ                         | 1/2                          |
|                                | Total                        | 3/6                          | Total                        | 1/6                          |
| LC-restricted IgA nephropathy/vasculitis | IgGκ                         | 0/8                          |                              |                              |
|                                | IgAλ                         | 3/14                         | IgAκ                         | 6/12                         |
|                                | Total                        | 3/22                         | Total                        | 6/12                         |

CUIMC, Columbia University Irving Medical Center; GBM, glomerular basement membrane; GN, glomerulonephritis; HLC, heavy and light chain; IF, immunofluorescence; LC, light chain; MN, membranous nephropathy; PGNMID, proliferative glomerulonephritis with monoclonal immunoglobulin deposits.

*These cases were stained with IgAκ and IgAλ HLC-IF.
malignancy. HLC-IF results revealed both IgGk and IgGλ in 4 of the 7 with monotypic ITG (57%), including 2 with IgG1k and 2 with IgG2k, and in the single patient with bitypic ITG. Not surprisingly, in 4 of the 5 cases with polytypic staining by HLC-IF, there was greater intensity of staining for the IgG-LC pair that had been originally identified in the monotypic deposits by conventional IF. Of note, in 3 of the 4 patients with chronic lymphocytic leukemia, the deposits were polytypic with HLC-IF.

There were 6 patients who had LC-restricted membranous nephropathy, including 3 with IgG1k monotypic deposits, 1 with IgG3k monotypic deposits, and 2 with bitypic IgG1k and IgG3k deposits. One patient with monotypic deposits (IgG1k) had chronic lymphocytic leukemia and 1 patient with bitypic deposits had lymphoma of mucosa-associated lymphoid tissue (with IgM paraprotein). The remaining 4 patients did not have paraproteinemia or hematolymphoid malignancy. HLC-IF results revealed staining for both IgGk and IgGλ in 1 patient with monotypic IgG1k deposits and in both patients with bitypic deposits by conventional IF.

Six patients had LC-restricted atypical antiglomerular basement membrane disease, including 2 with IgG1k-restriction, 3 with IgG1λ-restriction, and 1 with bitypic IgG1λ and IgG4λ. One patient with IgG1k deposits had a serum IgGk and free κ paraprotein, the remaining 5 had no evidence of paraproteinemia, and none had evidence of hematolymphoid malignancy. HLC-IF results revealed both IgGk and IgGλ in both cases with IgG1k restriction and in the case of bitypic IgG1λ and IgG4λ.

HLC-IF was performed on 3 biopsies with monotypic DNAJB9-associated fibrillary GN and IgG1k-restricted deposits. One patient had an IgGk serum paraprotein, but none had evidence of hematolymphoid malignancy. HLC-IF results revealed both IgGk and IgGλ in the 2 patients who lacked a detectable paraprotein and, oddly, were negative for both IgGk and IgGλ in the other patient.

We evaluated 22 biopsies with LC restricted, IgA-dominant staining including 16 cases of apparent IgA nephropathy and 6 with IgA vasculitis. Among the 22 patients, only 1 had a serum M-spike (IgGk and free κ) and none had a history of malignancy. HLC-IF result was positive solely for IgAk in all 8 cases with IgAk restriction by conventional IF. In contrast, HLC-IF results revealed both IgAk and IgAl in 3 of 14 biopsies (21%) with IgAl restriction by conventional IF. Notably HLC-IF results in 12 control cases revealed findings concordant with conventional IF.

Our results extend and refine the findings by Nasr et al. In our cohort, HLC-IF detected polytypic glomerular deposits in approximately 30% of cases that display monotypic deposits by conventional IF. HLC-IF seems most useful in monotypic or bitypic forms of membranous nephropathy, fibrillar GN, atypical antiglomerular basement membrane disease, and in a few cases of λ-restricted IgA nephropathy, because almost all with polytypic HLC-IF results had no evidence of hematolymphoid malignancy or paraproteinemia that matched the glomerular deposits. This was particularly notable for monotypic DNAJB9-associated fibrillary GN, as recent reports suggest that this entity should not be considered a form of MGRS.

HLC-IF was of limited utility in excluding monotypic deposits in PGNMID, with detection of both IgGk and IgGλ-heavy chain pairs in only 2 of 20 patients with PGNMID (10%), similar to the finding by Nasr et al. (2 of 10; 20%). This entity remains something of an enigma in that deposits reproducibly seem to have a monotypic composition despite the absence of a detectable paraprotein in 70% of patients. Similarly, HLC-IF was of limited utility in cases of K-restricted IgA nephropathy/vasculitis.

Importantly, our findings also suggest that the presence of both κ- and λ-heavy chain pairs by HLC-IF does not in and of itself exclude an association with paraproteinemia or hematolymphoid malignancy. Although coincidental associations cannot be excluded, this finding highlights the need for careful interpretation of HLC-IF results in the context of specific disease categories. In particular, among patients with monotypic ITG (most of whom have paraproteinemia or hematolymphoid malignancy), the combined results of conventional IF and HLC-IF suggest that, although monotypic deposits predominate in 2/3 cases, some of these cases have a smaller component of polytypic deposits that are best identified by HLC-IF.

Limitations of our data include the relatively small sample size, the limited availability of clinical data, and the inability to verify our data by an orthogonal non-antibody based method.

In summary, we report an independent series of kidney biopsy specimens evaluated with HLC-IF. Our findings largely validate the findings by Nasr et al. and expand the literature on the utility of HLC-IF in the evaluation of selected kidney diseases. More experience is needed to define the role of HLC-IF in routine kidney biopsy practice.

**DISCLOSURE**

All the authors declared no competing interests.

**ACKNOWLEDGMENTS**

The authors thank Yuancheng Wang at the Columbia Renal Pathology Laboratory for technical assistance with HLC-IF.
The authors thank the Binding Site (Birmingham, United Kingdom) for gifting the HLC-IF reagents used in this study.

SUPPLEMENTAL MATERIAL
Supplementary File (PDF)
Supplementary Methods.
Supplementary References.

REFERENCES
1. Nasr SH, Fidler ME, Said SM, Koepplin JW, Altamirano-Alonso JM, Leung N. Immunofluorescence staining for immunoglobulin heavy chain/light chain on kidney biopsies is a valuable ancillary technique for the diagnosis of monoclonal gammopathy-associated kidney diseases. *Kidney Int*. 2021;100:155–170. https://doi.org/10.1016/j.kint.2021.02.038

2. Best Rocha A, Larsen CP. Membranous glomerulopathy with light chain-restricted deposits: a clinicopathological analysis of 28 cases. *Kidney Int Rep*. 2017;2:1141–1148. https://doi.org/10.1016/j.ekir.2017.07.008

3. Nasr SH, Collins AB, Alexander MP, et al. The clinicopathologic characteristics and outcome of atypical anti-glomerular basement membrane nephritis. *Kidney Int*. 2016;89:897–908. https://doi.org/10.1016/j.kint.2016.02.001

4. Kudose S, Canetta P, Andeen NK, et al. Diagnostic approach to glomerulonephritis with fibrillar IgG deposits and light chain restriction. *Kidney Int Rep*. 2021;6:936–945. https://doi.org/10.1016/j.ekir.2021.01.001

5. Said SM, Leung N, Alexander MP, et al. DNAJB9-positive monotypic fibrillary glomerulonephritis is not associated with monoclonal gammopathy in the vast majority of patients. *Kidney Int*. 2020;98:498–504. https://doi.org/10.1016/j.kint.2020.02.025

6. Nasr SH, Kudose SS, Said SM, et al. Immunotactoid glomerulopathy is a rare entity with monoclonal and polyclonal variants. *Kidney Int*. 2021;99:410–420. https://doi.org/10.1016/j.kint.2020.07.037